LM2010_banner-logo

 

Hepatitis B Abstracts

 

 

Peginterferon

 

 

 

DAAs

 

·        Adefovir

o   484. Adding Adefovir Compared with Switching to Entecavir in Patients with Lamivudine-Resistant Chronic Hepatitis B (ACE Study) - A Multicenter Prospective Randomized Study: One-Year Interim Analysis. 

 

·        Entecavir

o   478. Long-Term Entecavir Treatment for up to 5 Years in Asians with HBeAg-positive Nucleos(t)ide naļve Chronic Hepatitis B: Results from ETV-022 and -901. (Updated October 31, 2010)

o   485. Efficacy and Safety of Entecavir in Nucleos(t)ide Naļve Asians with HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027.  (Updated October 31, 2010)

 

·        Telbivudine

o   212. A Prospective and Open-Label Study for the Efficacy and Safety of Telbivudine(Ltd) in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus (HBV) to the Infants. 

o   491. Telbivudine Switch in Lamivudine Pretreated Chronic Hepatitis B Patients Provides Sustained Viral Suppression for 2 Years. 

 

 

·        Tenofovir

o   134. HBV rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir DF (TDF) Monotherapy or Combination Therapy with Emtricitabine (FTC): an Evaluation of Early Viral Load Decay Kinetics. 

o   136. Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil: Final Week 168 Results.

o   137. 4 Year Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients with High Viral Load (HBV DNA ≥9 log10 copies/mL): Preliminary Analysis.

o   138. Tenofovir (TDF) for Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (ADV) or ADV/LAM Treatment: Results of the OptiB Italian Multicenter Prospective Open Label Study.

o   476. Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102): Preliminary Analysis

o   477. Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103): Preliminary Analysis.

o   481. Four Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Preliminary Analysis.

 

 

Miscellaneous

 

·        LB-17. Immunogenicity of Two Doses of Investigational HEPLISAV™ (HBsAg-ISS) Compared to Three Doses of Licensed Hepatitis B Vaccine (ENGERIX-B®) in Diabetics.